Primary pulmonary hypertension (PPH) is a serious disease of unknown cause in which small arteries in the lungs become obstructed. Mean survival is less than 3 years, and women develop PPH twice as commonly as men. It is familial (FPPH) in about 6% of cases. The National FPPH Registry was established in 1994 to collect and analyze family history and clinical data from PPH families to better characterize the disease phenotype as well as to identify the underlying genetic etiology. Through the collection of 72 families, FPPH has been shown to be inherited as an autosomal dominant disorder, with incomplete penetrance and genetic anticipation. Micro-satellite marker studies in six families have identified linkage to chromosome 2q31 without evidence of genetic heterogeneity. The current application will expand the Registry in order to obtain enough PPH families to localize and clone the PPH gene, and support the DNA bank for these and further studies. Other goals include prospective and biochemical mediator studies of obligate gene carriers, who do not have clinically evident PPH.
This aim will determine which mediators first become abnormal during developing PPH, and define the natural history of pre-symptomatic diseases. In addition, the Registry will broaden its scope to include sporadic PPH patients, including those who have used appetite suppressant medications, who will be screened for gene mutations. The identification of the PPH gene and its mechanism of disease will provide pivotal knowledge about PPH, but its importance may b broader because PPH is an index disease with pathologic changes identical to those seen in vessels of many common diseases such as congenital heart or connective tissue diseases. Familial PPH demonstrates many unusual transmission characteristics, including incomplete penetrance and genetic anticipation, where the disease occurs at younger ages in subsequent generations. Genetic counseling will be provided, both as a service for PPH families, but also as a model toe examine the impact on individuals and families who receive it, with special emphasis on the impact of incomplete penetrance and genetic anticipation. The only known biologic explanation of genetic anticipation is trinucleotide repeat expansion (TRE), which is currently recognized as the basis of 11 neurologic diseases. If TRE is found to be the molecular abnormality of the PPH gene, FPPH will be the first reported non-neurologic disease due to this mechanism. If another undiscovered mechanisms for genetic anticipation exists, it will have major implications for the understanding of human molecular biology. In the future we will also research for modifier genes to explain the variable expression or course of disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL048164-07
Application #
6165027
Study Section
Lung Biology and Pathology Study Section (LBPA)
Project Start
1994-04-01
Project End
2004-02-29
Budget Start
2000-03-01
Budget End
2001-02-28
Support Year
7
Fiscal Year
2000
Total Cost
$358,266
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Ma, Lijiang; Roman-Campos, Danilo; Austin, Eric D et al. (2013) A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 369:351-361
Runo, James R; Vnencak-Jones, Cindy L; Prince, Melissa et al. (2003) Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 167:889-94
Kuhn, Karl P; Byrne, Daniel W; Arbogast, Patrick G et al. (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167:580-6
Runo, James R; Loyd, James E (2003) Primary pulmonary hypertension. Lancet 361:1533-44
Loyd, James E (2002) Parker B. Francis Lecture. Genetics and gene expression in pulmonary hypertension. Chest 121:46S-50S
Loyd, James E (2002) Genetics and pulmonary hypertension. Chest 122:284S-286S
Holcomb, B W; Loyd, J E; Byrd 3rd, B F et al. (2001) Iatrogenic paradoxical air embolism in pulmonary hypertension. Chest 119:1602-5
Trembath, R C; Thomson, J R; Machado, R D et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345:325-34
Doyle, T P; Loyd, J E; Robbins, I M (2001) Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am J Respir Crit Care Med 164:657-60
Thomas, A Q; Gaddipati, R; Newman, J H et al. (2001) Genetics of primary pulmonary hypertension. Clin Chest Med 22:477-91, ix

Showing the most recent 10 out of 22 publications